Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Virology

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jcv.2007.12.015PMID 18316243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update of the Drug Resistance Mutations in HIV-1.

  2008cited by this paper
• Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection.

  2007cited by this paper
• Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

  2007cited by this paper
• Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis-Coinfected Patients With and Without Antiretroviral Therapy

  2006cited by this paper
• Clinical and genotypic correlates of mutation K65R in HIV‐infected patients failing regimens not including tenofovir

  2006cited by this paper
• Resistance development over 144 weeks in treatment‐naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 *

  2006cited by this paper
• Update of the drug resistance mutations in HIV-1: Fall 2006.

  2006cited by this paper
• Antiretroviral drug resistance and resistance testing.

  2005cited by this paper
• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

  2004cited by this paper
• Preventing and Managing Antiretroviral Drug Resistance

  2004cited by this paper
• Tenofovir disoproxil fumarate

  2003cited by this paper
• Thailand's Do-It-Yourself Therapy

  2003cited by this paper
• A Novel Genetic Pathway of Human Immunodeficiency Virus Type 1 Resistance to Stavudine Mediated by the K65R Mutation

  2003cited by this paper
• Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance.

  2003cited by this paper
• Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity

  2002cited by this paper
• The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.

  2002cited by this paper
• A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

  1998cited by this paper

• Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors

  2016cites this paper
• Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011

  2015influential citation
• Characterization of drug resistance mutations in ART-naïve HIV-1 infected children in Northern Vietnam

  2015cites this paper
• Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV Type 1 Infected Patients attending Clinics in Kinshasa, Democratic Republic of Congo

  2015cites this paper
• Deep sequencing of HIV: clinical and research applications.

  2014cites this paper
• The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance

  2014cites this paper
• Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria

  2013cites this paper
• Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months’ antiretroviral therapy experience in Cameroon

  2013cites this paper
• HIV drug resistance among adults and children in sub-Saharan Africa

  2013cites this paper
• Drug-resistant HIV-1 in sub-Saharan Africa: clinical and public health studies

  2013cites this paper
• Increased Risk of Q151M and K65R Mutations in Patients Failing Stavudine-Containing First-Line Antiretroviral Therapy in Cambodia

  2013cites this paper
• HIV Type 1 Virological Response and Prevalence of HIV Type 1 Drug Resistance Among Patients Receiving Antiretroviral Therapy, Shandong, China

  2012cites this paper
• Suivi immuno-virologique et thérapeutique de l'infection à VIH chez des enfants suivis au CHU pédiatrique de Ouagadougou (collaboration ESTHER)

  2012cites this paper
• Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program.

  2012cites this paper
• A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi.

  2012cites this paper
• Prevalence of Low-Level HIV-1 Variants with Reverse Transcriptase Mutation K65R and the Effect of Antiretroviral Drug Exposure on Variant Levels

  2011cites this paper
• Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa

  2011cites this paper
• The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.

  2011cites this paper
• Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010

  2010cites this paper
• International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase

  2010cites this paper
• Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.

  2010cites this paper
• Prevalence of the K65R resistance reverse transcriptase mutation in different HIV‐1 subtypes in Israel

  2009cites this paper
• The use of resistance testing in the management of HIV-1-infected patients

  2009cites this paper
• The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

  2009cites this paper
• HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme

  2009cites this paper
• The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

  2009cites this paper
• The naming of strep, with apologies to T. S. Eliot.

  2009cites this paper
• Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya

  2009cites this paper
• Development of an Allele-Specific PCR for Detection of the K65R Resistance Mutation in Patients Infected with Subtype C Human Immunodeficiency Virus Type 1

  2009cites this paper
• Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries.

  2009cites this paper
• Slow accumulation of HIV resistance mutations: implications for resource-limited settings?

  2009cites this paper
• Clinical and Genotypic Findings in HIV-Infected Patients With the K65R Mutation Failing First-Line Antiretroviral Therapy in Nigeria

  2009cites this paper
• Perspectives on treatment failure with thymidine analogue-based first-line regimens in resource-limited settings.

  2009cites this paper
• HAART for children with treatment failure

  2009cites this paper
• Clinical Implications of Reverse Transcriptase Inhibitor Resistance

  2009cites this paper